Literature DB >> 2010630

Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5.

J D Baumgartner1, D Heumann, T Calandra, M P Glauser.   

Abstract

To investigate whether immunization with Escherichia coli J5 boiled cells induces antibodies directed at deep core structures, antibodies against J5 lipopolysaccharide (LPS), Re LPS, and lipid A were measured in the serum of 70 volunteers before and 2 weeks after immunization. To improve the sensitivity and the specificity of ELISA, complexes of core LPS with high-density lipoproteins were used instead of free core LPS as antigens. A median three-fold increase in antibodies directed against J5 LPS was observed, but no significant increase in the antibodies against Re LPS or lipid A was found. Since J5 antiserum did not react with several smooth LPS or with Re LPS and lipid A, cross-reactivity could not be demonstrated. Thus, immunization of volunteers with E. coli J5 produced a modest specific antibody response against J5 LPS. The mechanism of protection previously observed with J5 antiserum remains unclear.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2010630     DOI: 10.1093/infdis/163.4.769

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls.

Authors:  E Konadu; J Shiloach; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Monoclonal antibodies in sepsis and septic shock.

Authors:  C J Hinds
Journal:  BMJ       Date:  1992-01-18

3.  Synthesis and immunogenicity evaluation of Salmonella enterica serovar Paratyphi A O-specific polysaccharide conjugated to diphtheria toxoid.

Authors:  Aamir Ali; So J An; Changfa Cui; Abdul Haque; Rodney Carbis
Journal:  Hum Vaccin Immunother       Date:  2014-03-06       Impact factor: 3.452

4.  Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam.

Authors:  E Y Konadu; F Y Lin; V A Hó; N T Thuy; P Van Bay; T C Thanh; H B Khiem; D D Trach; A B Karpas; J Li; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

5.  Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.

Authors:  J H Passwell; E Harlev; S Ashkenazi; C Chu; D Miron; R Ramon; N Farzan; J Shiloach; D A Bryla; F Majadly; R Roberson; J B Robbins; R Schneerson
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

6.  Preparation and preclinical evaluation of a novel liposomal complete-core lipopolysaccharide vaccine.

Authors:  E Bennett-Guerrero; T J McIntosh; G R Barclay; D S Snyder; R J Gibbs; M G Mythen; I R Poxton
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

Review 7.  Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients.

Authors:  A Cometta; J D Baumgartner; M P Glauser
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes.

Authors:  R K Gupta; W Egan; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

9.  A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides.

Authors:  F E Di Padova; H Brade; G R Barclay; I R Poxton; E Liehl; E Schuetze; H P Kocher; G Ramsay; M H Schreier; D B McClelland
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

10.  Milk and serum J5-specific antibody responses, milk production change, and clinical effects following intramammary Escherichia coli challenge for J5 vaccinate and control cows.

Authors:  David J Wilson; Bonnie A Mallard; Jeanne L Burton; Ynte H Schukken; Yrjo T Gröhn
Journal:  Clin Vaccine Immunol       Date:  2007-04-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.